



- (51) **International Patent Classification:**
A61K 39/395 (2006.01) *A61P 37/02* (2006.01)
- (21) **International Application Number:**
PCT/US2023/075600
- (22) **International Filing Date:**
29 September 2023 (29.09.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/377,847 30 September 2022 (30.09.2022) US
- (71) **Applicant: FORTE SUBSIDIARY, INC.** [US/US]; 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247 (US).
- (72) **Inventor: WAGNER, Paul A.**; 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247 (US).
- (74) **Agent: MAY, Scott et al.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

- (54) **Title:** ANTI-CD122 ANTIBODIES AND USES THEREOF




FIG. 11

- (57) **Abstract:** Provided herein, in certain aspects, are anti-CD122 antibodies and pharmaceutical compositions which comprise anti-CD122 antibodies. In some embodiments, the anti-CD122 antibodies and the pharmaceutical compositions comprising anti-CD122 antibodies can be used for targeting CD122-expressing tissues and cells.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

10 May 2024 (10.05.2024)